IGSF21

Across TCGA pan-cancer cohorts, IGSF21 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated IGSF21 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IGSF21 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated IGSF21 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUAD, and OV are the cancer types where IGSF21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.625	.005	34	view →
LUAD	OS	Median	II,III,IV	0.163	0.750	.001	18	view →
OV	OS	Median	III,IV	0.427	0.685	.041	10	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
READ	OS	Median	All	0.281	0.830	.006	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	III,IV	0.140	0.696	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

IGSF21–UCEC (DFS)

Open the UCEC breakdown →